NOVO NORDISK : Bernstein remains Neutral

Published on 2025-06-12 at 02:58

MarketScreener with dpa-AFX Analyser

Bernstein confirms his opinion on the stock and remains Neutral. The target price continues to be set at DKK 620.

Latest news about Novo Nordisk A/S

Fangzhou Inc. and Novo Nordisk Signs Collaboration Memorandum to Establish A New Ecosystem for Health Management	07-18	CI
NOVO NORDISK : UBS keeps its Buy rating	07-18	ZD
NOVO NORDISK : Deutsche Bank reaffirms its Buy rating	07-18	ZD
Many US employers plan to pare health benefits as weight-loss spending soars	07-17	RE
Gerresheimer calls a halt to discussions on potential takeover	07-16	RE
Gerresheimer calls a halt to discussions on potential takeover	07-16	RE
Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says	07-16	RE
NOVO NORDISK : UBS lowers target price	07-16
Berenberg Keeps Novo Nordisk at Hold Amid Wegovy Volume Growth Data Focus	07-16	MT
NOVO NORDISK : Receives a Buy rating from UBS	07-16	ZD
European shares fall on healthcare, financials drag; focus on US-EU trade deal	07-15	RE
European shares fall on healthcare, financials drag; focus on US-EU trade deal	07-15	RE
Kailera touts late-stage win for weight-loss drug in China	07-15	RE
Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales	07-15	FW
NOVO NORDISK : Berenberg sticks Neutral	07-15	ZD
Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	07-14	FW
Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	07-14	MT
Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	07-13	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
NOVO NORDISK : Gets a Buy rating from UBS	07-11	ZD
Wall Street Waits to Hear the Numbers	07-11
Mining, healthcare prop up European shares; US-EU trade talks in focus	07-10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE